Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DKd in High-Risk Smoldering Multiple Myeloma
NCT04933539Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2022
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab, carfilzomib, dexamethasone in smoldering multiple myeloma (SMM), sponsored by National Cancer Institute. Started Oct 2022; status: active, not recruiting.
02
Drugs
daratumumabcarfilzomibdexamethasone
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT04933539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04933539.